TheraRadar
Clinical-Stage Companies / Ascletis Pharmaceuticals

Ascletis Pharmaceuticals

Pre-Approval PRO BETA
🔴

Stale Activity

No new clinical trials started in 2+ years. Activity may be declining or company may be focusing on existing programs. Last trial started: 4/18/2024

25
Total Trials
5
Phase 3
7
Phase 2
1
Recruiting
173
Score

Pipeline by Phase

Phase 3
5
Phase 2
7
Phase 1
14

Therapeutic Focus

Healthy Chronic Hepatitis C Acne SARS CoV 2 Infection HCV

Clinical Trials (25)

NCT06248008 Phase 3 COMPLETED

A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne Vulgaris

Started: 4/18/2024

NCT06192264 Phase 3 COMPLETED

A Study to Evaluate the Safety and Efficacy of ASC40 (Denifanstat) Tablets in the Treatment of Patients With Moderate to Severe Acne Vulgaris

Started: 1/23/2024

NCT05118776 Phase 3 ACTIVE NOT RECRUITING

Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM

Started: 1/21/2022

NCT03020082 Phase 3 COMPLETED

Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III

Started: 6/1/2016

NCT05104125 Phase 2 COMPLETED

Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne Vulgaris

Started: 1/12/2022

NCT04465890 Phase 2 COMPLETED

A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients

Started: 7/17/2020

NCT05330143 Phase 2 COMPLETED

Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV

Started: 6/28/2022

NCT05107778 Phase 2 COMPLETED

Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBV

Started: 1/10/2022

NCT03020095 Phase 2 COMPLETED

Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan

Started: 8/1/2015

NCT03362814 Phase 2 COMPLETED

Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.

Started: 7/1/2017

NCT03020004 Phase 2 COMPLETED

Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II

Started: 1/1/2016

NCT05287399 Phase 1 COMPLETED

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors

Started: 8/2/2022

NCT05718518 Phase 1 COMPLETED

Study to Evaluate Safety, Tolerability, PK and the Food Effect on PK of ASC11/RTV Tablets in Healthy Subjects

Started: 1/13/2023

NCT05596045 Phase 1 WITHDRAWN

Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients

Started: 11/28/2022

NCT05523141 Phase 1 COMPLETED

Study to Evaluate Safety, Tolerability, Pharmacokinetics and the Food Effect on PK of ASC10 Tablets in Healthy Subjects

Started: 10/7/2022

NCT04965337 Phase 1 COMPLETED

Study to Evaluate Safety, Tolerability and Pharmacokinetics of ASC42 in Chinese Healthy Subjects

Started: 7/11/2021

NCT04843449 Phase 1 COMPLETED

Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics of ASC40 in Healthy Subjects

Started: 4/4/2021

NCT04527250 Phase 1 COMPLETED

A Study of the Relative Bioavailability of ASC41 in Healthy Subjects

Started: 9/16/2020

NCT04547894 Phase 1 COMPLETED

A Study of the Pharmacokinetics of ASC09F in Healthy Subjects

Started: 11/9/2020

NCT04358523 Phase 1 COMPLETED

A Study of the Relative Bioavailability of ASC18 Tablets vs Reference Tablets in Healthy Volunteers

Started: 3/20/2020

NCT04352361 Phase 1 COMPLETED

Ascending Single-dose Study to Evaluate TVB-2640 in Chinese Healthy Subjects

Started: 4/2/2020

NCT03430830 Phase 1 COMPLETED

A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China

Started: 1/15/2018

NCT03020134 Phase 1 COMPLETED

Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers China

Started: 7/15/2016

NCT03288636 Phase 1 COMPLETED

Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China

Started: 8/8/2017

NCT03019991 Phase 1 COMPLETED

Safety, Tolerability and Pharmacokinetics of Danoprevir/r in Healthy Volunteers China

Started: 10/1/2015

Drug Candidates

ASC61 200 mg 1 ASC61 200 mg 2 ASC61 300 mg ASC61 400 mg ASC61 600 mg ASC61 800 mg ASC40 ASC40 25mg ASC40 50mg ASC40 75mg
Activity Status: Stale
Last Trial Started: 4/18/2024
Last Trial Ended: 11/12/2025
Trials (12 months): 0
Completed Trials: 23
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.